3-(2,2,2-trimethylhydrazine)propionate has been researched along with Ventricular Dysfunction, Left in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cirule, H; Dambrova, M; Kigitovica, D; Korzh, S; Liepinsh, E; Makrecka-Kuka, M; Skride, A; Videja, M; Vilks, K; Vilskersts, R | 1 |
| Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT | 1 |
| Iushchuk, EN; Khadzegova, AB; Sadulaeva, IA; Shkol'nik, EL; Vakhromeeva, MN; Vasiuk, IuA; Vit'ko, NK | 1 |
| Baiandin, NL; Gordeev, IG; Il'ina, EE; Kuznechevskiĭ, FV; Liusov, VA | 1 |
| Asaka, N; Hayashi, Y; Kanno, T; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M | 1 |
2 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Agents; Drug Therapy, Combination; Humans; Male; Methylhydrazines; Middle Aged; Mitochondrial Trifunctional Protein; Multienzyme Complexes; Myocardial Infarction; Ventricular Dysfunction, Left | 2003 |
[Comparative trial of efficacy of trimethasidine MB and 3-(2,2,2-trimethylhydrasine) propionate dihydrate in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Diuretics; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Positron-Emission Tomography; Trimetazidine; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
3 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Protective Effects of Meldonium in Experimental Models of Cardiovascular Complications with a Potential Application in COVID-19.
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Endothelium; Heart Failure; Heart Ventricles; Hydrogen Peroxide; Lung; Male; Methylhydrazines; Mice, Inbred C57BL; Mitochondria; Oxygen Saturation; Rats, Sprague-Dawley; Reactive Oxygen Species; Reperfusion Injury; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2021 |
[Derangements of contractility of left ventricular myocardium in patients subjected to coronary bypass surgery. Methods of their correction].
Topics: Adult; Aged; Angina Pectoris; Cardiotonic Agents; Coronary Artery Bypass; Female; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Contraction; Postoperative Complications; Trimetazidine; Ventricular Dysfunction, Left | 2007 |
Beneficial effects of MET-88 on left ventricular dysfunction and hypertrophy with volume overload in rats.
Topics: Animals; Body Weight; Cardiac Volume; Cardiomegaly; Cardiovascular Agents; Heart; Hemodynamics; Male; Methylhydrazines; Organ Size; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Renin; Ventricular Dysfunction, Left | 1999 |